EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 173 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease May 29, 2020 The ecDNA story – catching the mastermind behind cancer evolution February 20, 2023 FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma March 12, 2021 Load more HOT NEWS Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... Shelter Puppies Got A Private Tour Of The Georgia Aquarium
